We, therefore, predicted for A375 cells that a combination of trametinib (a pMEK1/2 inhibitor, commonly used for melanoma in clinics; also inhibits pS627,28) and dasatinib (a multi-kinase inhibitor targeting also PDGFRβ) should effectively target the three unbalanced processes that constitute the PaSSS of these cells (Fig. 5b). The gene discussed is PDGFRB; the disease is melanoma.